Real-life evidence in allergen immunotherapy: Moving forward with mHealth apps DOI
Bernardo Sousa‐Pinto, Oliver Pfaar, Jean Bousquet

et al.

Allergologie select, Journal Year: 2023, Volume and Issue: 7(1), P. 47 - 56

Published: Jan. 1, 2023

The efficacy and safety of allergen immunotherapy (AIT) in allergic rhinitis has been classically assessed using randomized controlled trials (RCTs). However, RCTs may have limitations their external validity, evidence be complemented with that from real-world studies. We aimed to review the mHealth apps can used for retrieving data on AIT rhinitis.We applied an automatic tool identify (available Google Play Apple App stores) assess patients under rhinitis. Apps meeting inclusion criteria were reviewed, corresponding scientific was assessed.We identified five publications context rhinitis: AirRater, AllergyMonitor, MASK-air, Husteblume, Pollen App. Of those, only MASK-air AllergyMonitor enabled comparison reported symptoms among treated vs. not-treated AIT. also allowed development combined symptom-medication scores as endpoints trials. mobile technology improve adherence is set support prescription by a more precise identification pollen season.Mobile health tools allow collection large volumes useful generating hypotheses such require confirmation epidemiological studies RCTs.

Language: Английский

Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis DOI Creative Commons
Jean Bousquet, Erik Melén, Tari Haahtela

et al.

Allergy, Journal Year: 2023, Volume and Issue: 78(5), P. 1169 - 1203

Published: Feb. 17, 2023

Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of "one-airway-one-disease," coined over 20 years ago, is a simplistic approach links between upper- lower-airway allergic diseases. With new data, it time to reassess concept. This article reviews (i) observations led Allergic Rhinitis its Impact on Asthma (ARIA), (ii) insights into polysensitization multimorbidity, (iii) advances mHealth for novel phenotype definitions, (iv) confirmation canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, (vii) concepts onset rhinitis multimorbidity. One recent concept, bringing together diseases with skin, gut, neuropsychiatric multimorbidities, "Epithelial Barrier Hypothesis." review determined "one-airway-one-disease" does not always hold true several disease can be defined. These include an extreme "allergic" (asthma) combining asthma, conjunctivitis. alone asthma multimorbidity represent two distinct following differences: transcriptomic background (Toll-Like Receptors IL-17 as local disease; IL-33 IL-5 non-allergic systemic disease), allergen sensitization patterns (mono- or pauci-sensitization versus polysensitization), severity symptoms, response. In conclusion, (local disease) (systemic should considered diseases, possibly modulated by microbiome, may model understanding epidemics chronic autoimmune

Language: Английский

Citations

55
Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air®approach DOI Creative Commons
Jean Bousquet,

Josep M Antó,

Bernardo Sousa‐Pinto

et al.

Clinical and Translational Allergy, Journal Year: 2023, Volume and Issue: 13(1)

Published: Jan. 1, 2023

MASK-air

Language: Английский

Citations

34
MASK-air: An OECD (Organisation for Economic Co-operation and Development) Best Practice for Public Health on Integrated Care for Chronic Diseases DOI Creative Commons
Jean Bousquet, Bernardo Sousa‐Pinto, Josep M. Antó

et al.

The Journal of Allergy and Clinical Immunology In Practice, Journal Year: 2024, Volume and Issue: 12(8), P. 2010 - 2016.e7

Published: March 22, 2024

In the recent report of Organisation for Economic Co-operation and Development (OECD) on Best Practices (BPs) Integrating Care to Prevent Manage Chronic Diseases, an app rhinitis asthma (MASK-air [Mobile Airways Sentinel networK airway diseases]) has been listed. The OECD is a reliable source evidence-based policy analysis economic data largely used by governments. It published several BPs public health. On May 10, 2023, 13 Diseases in European Union. did not cover all models integrated care; rather, it "focuse(d) those that are key strategic interest makers." New MASK-air studies (not report) include equity, usability old-age adults, impact, quality life, allergen immunotherapy. freely available iOS Android 30 countries recently introduced United States. BP represents model digitally enabled, patient-centered care chronic diseases using holistic approach shared decision making.

Language: Английский

Citations

8
Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK‐air Study DOI Creative Commons
Bernardo Sousa‐Pinto, Elı́sio Costa, Rafael José Vieira

et al.

Clinical & Experimental Allergy, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 16, 2025

Adherence to rhinitis treatment has been insufficiently assessed. We aimed use data from the MASK-air mHealth app assess adherence oral antihistamines (OAH), intra-nasal corticosteroids (INCS) or azelastine-fluticasone in patients with allergic rhinitis. included regular European users self-reported and reporting at least 1 day of OAH, INCS azelastine-fluticasone. assessed weeks during which answered questionnaire on all days. restricted our analyses provided between January June, encompass pollen seasons across different countries. analysed symptoms using visual analogue scales (VASs) combined symptom-medication score (CSMS), performing stratified by weekly levels. Medication was computed as proportion days reported medication use. Sensitivity were performed considering most missing months 4 data. 8212 complete (1361 users). (use > 80% days) specific drug classes ranged 31.7% for 38.5% OAH. Similar found without asthma, except (better asthma patients). VAS CSMS levels increased no full adherence, INCS. A higher uncontrolled observed adherence. In weeks, 41.2% co-medication. The sensitivity displayed similar results. high MASK-air. Different patterns compared OAH that are likely impact guidelines.

Language: Английский

Citations

1
Immunomodulatory properties of mesenchymal stem cells: A potential therapeutic strategy for allergic rhinitis DOI Open Access
Ming Wang, Ning Zhao, Chengshuo Wang

et al.

Allergy, Journal Year: 2023, Volume and Issue: 78(6), P. 1425 - 1440

Published: March 28, 2023

Abstract Allergic rhinitis is a highly prevalent chronic inflammatory disorder of the nasal mucosa that poses significant burden on patients' health and quality life. Current therapies for allergic are unable to reinstate immune homeostasis or restricted by specific allergens. Potential therapeutic strategies urgently needed. Mesenchymal stem cells (MSCs) immune‐privileged, have strong immunomodulatory effects, can be easily isolated from various sources. Thus, MSC‐based demonstrate potential treating diseases. Recently, numerous studies investigated effects MSCs in animal models rhinitis. Here, we review mechanisms airway inflammation, especially rhinitis, highlight recent research regarding modulation cells, discuss clinical therapy

Language: Английский

Citations

20
The Allergic Rhinitis and Its Impact on Asthma (ARIA) Approach of Value-Added Medicines: As-Needed Treatment in Allergic Rhinitis DOI Creative Commons
Jean Bousquet,

Mondher Toumi,

Bernardo Sousa‐Pinto

et al.

The Journal of Allergy and Clinical Immunology In Practice, Journal Year: 2022, Volume and Issue: 10(11), P. 2878 - 2888

Published: Aug. 4, 2022

Language: Английский

Citations

27
Academic Productivity of Young People With Allergic Rhinitis: A MASK-air Study DOI Creative Commons
Rafael José Vieira, N. Pham‐Thi, Josep M. Antó

et al.

The Journal of Allergy and Clinical Immunology In Practice, Journal Year: 2022, Volume and Issue: 10(11), P. 3008 - 3017.e4

Published: Aug. 23, 2022

Language: Английский

Citations

25
Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: An EAACI position paper DOI Creative Commons
Jasper H. Kappen, Zuzana Diamant, Ioana Agache

et al.

Allergy, Journal Year: 2023, Volume and Issue: 78(11), P. 2835 - 2850

Published: July 14, 2023

In allergic asthma patients, one of the more common phenotypes might benefit from allergen immunotherapy (AIT) as add-on intervention to pharmacological treatment. AIT is a treatment with disease-modifying modalities, evidence for efficacy based on controlled clinical trials following standardized endpoint measures. However, so far there lack consensus endpoints in trials. The aim task force (TF) European Academy Allergy and Clinical Immunology (EAACI) evaluating several outcome measures asthma.The domains asthmatic patients have been evaluated this position paper (PP): (i) exacerbation rate, (ii) lung function, (iii) ICS withdrawal, (iv) symptoms rescue medication use, (v) questionnaires (PROMS), (vi) bronchial/nasal provocation, (vii) exposure chambers (AEC) (viii) biomarkers.Exacerbation rate can be used reliable objective primary outcome; however, limited due different definitions exacerbation. time after withdrawal first considered measure. Besides, advantages disadvantages implications further are elaborated PP.This EAACI-PP aims highlight important aspects current by critically their applicability AIT.

Language: Английский

Citations

15
Artificial Intelligence–Supported Development of Health Guideline Questions DOI
Bernardo Sousa‐Pinto, Rafael José Vieira, Manuel Marques‐Cruz

et al.

Annals of Internal Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 23, 2024

Guideline questions are typically proposed by experts.

Language: Английский

Citations

4
Allergen sensitization patterns: Allergic rhinitis with multimorbidity versus alone—A real‐world study DOI Creative Commons

Yating Li,

YE Qiqing,

Yaxin Lu

et al.

Clinical and Translational Allergy, Journal Year: 2025, Volume and Issue: 15(1)

Published: Jan. 1, 2025

Language: Английский

Citations

0